Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,981 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride (NaCl) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarker Assessment of Glutamatergic Target Engagement

NCT02134951
View directory record Official record
Conditions
Healthy Controls
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 14, 2026, 6:50 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Post C-Section Pain Control Using EXPAREL

NCT03377595
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Exparel
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 14, 2026, 6:50 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity

NCT03318094
View directory record Official record
Conditions
Insulin Resistance, Healthy, Obesity
Interventions
Phentolamine, Saline, Sodium Nitroprusside
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Not listed Phase 4 Interventional

Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19

NCT04603794
View directory record Official record
Conditions
COVID-19
Interventions
0.5% Povidone Iodine, 0.12% Chlorhexidine Gluconate Mouth Rinse, 1% Hydrogen Peroxide, 0.9% Normal Saline
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 14, 2026, 6:50 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed

NCT04942340
View directory record Official record
Conditions
Emergence From Anesthesia
Interventions
Atipamezole & Caffeine, Dexmedetomidine Hydrochloride & Saline
Drug
Lead sponsor
University of Chicago
Other
Eligibility
22 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H7N7 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT01083615
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
20
States / cities
La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

NCT00616980
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
CD34-positive cells, Saline and 5% autologous plasma
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 14, 2026, 6:50 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

NCT03505060
View directory record Official record
Conditions
HIV Infections
Interventions
DNA CON-S env, IHV01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 14, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

NCT06150742
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Niyad (nafamostat mesylate), Placebo (0.9% NaCl)
Device
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis

NCT02623959
View directory record Official record
Conditions
Advanced Cancers, Malignant Pleural Effusions
Interventions
Questionnaires, Fentanyl Patch, Fentanyl (IV), Saline, Doxycycline, Phone Calls
Behavioral · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis

NCT03717896
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
200mg IV thiamine in 50mL 0.9% saline, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

NCT04545060
View directory record Official record
Conditions
Covid19
Interventions
VIR-7831 (sotrovimab), Placebo
Biological · Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
63
States / cities
Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction

NCT02161705
View directory record Official record
Conditions
Postoperative Pain, Postoperative Nausea and Vomiting, Quality of Life
Interventions
Ropivacaine, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

NCT06329661
View directory record Official record
Conditions
Dry Eye Disease, Endothelial Cell
Interventions
Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

NCT01595386
View directory record Official record
Conditions
Heart Disease Congenital Complex
Interventions
Hydrocortisone, Normal Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 28 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin to Enhance Alcohol Behavioral Couple Therapy (ABCT)

NCT03846505
View directory record Official record
Conditions
Alcohol Use Disorder, Couples
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 14, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

The CRISIS Prevention Study

NCT00395161
View directory record Official record
Conditions
Sepsis
Interventions
Metoclopramide, Zinc, Glutamine, Selenium, saline, sterile water, selenium, whey-protein
Drug · Dietary Supplement · Other
Lead sponsor
Michael Dean
Other
Eligibility
12 Months to 17 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Oct 14, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

NCT00622505
View directory record Official record
Conditions
Multiple Myeloma
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
42
States / cities
Casa Grande, Arizona • La Verne, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 14, 2026, 6:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers

NCT04036305
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Anesthesia, Local
Interventions
0.9% Sodium Chloride Injection, Lidocaine Injection 2%, Bupivacaine Injection 0.5%
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 6:50 AM EDT